SEC 13F Intelligence

Consonance Capital Management LP / KRYS

Consonance Capital Management LP’s Krystal Biotech Inc Position

Does Consonance Capital Management LP own Krystal Biotech Inc (KRYS)? Not currently — the last reported position was 654.6K shares worth $28M in Q1 2020; the fund’s latest 13F (Q3 2022) no longer reports it.

Position Value
$28M
Q1 2020
Shares
654.6K
% of Portfolio
+2.11%
Quarters Held
4
position exited

Position History KRYS

Reported value by quarter
Q2 ’19: $7MQ2 ’19Q3 ’19: $8MQ3 ’19Q4 ’19: $11MQ4 ’19Q1 ’20: $28MQ1 ’20filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2020654.6K$28M+2.11%
Q4 2019203.8K$11M+0.69%
Q3 2019224.1K$8M+0.77%
Q2 2019182.1K$7M+0.52%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Consonance Capital Management LP’s full portfolio or all institutional holders of KRYS.